Phase 4 Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 78 years old (who have not yet turned 79)
- People, or their legal representative, who are willing to give consent before any study procedures begin
- People who have had an ischemic stroke (caused by a blockage, not bleeding) that has been confirmed by a CT scan or MRI before joining the trial
- People who arrived for treatment within 24 hours of stroke symptoms starting, who had little to no disability before the stroke, and whose stroke caused moderate-to-severe symptoms on standard medical rating scales — but who are not deeply unresponsive (confirm with trial site for exact score details)
- People whose first dose of the study drug (Sovateltide) can be given within 24 hours of when symptoms began — or, for strokes that happened during sleep, within 24 hours of when the person was last known to be well
- People who are expected to be available to complete the full course of the study drug and attend all follow-up visits
- People who previously had a stroke but fully recovered before having a new stroke may also be considered
Who may not be able to join:
- People who are receiving, or are being considered for, a procedure to physically open or treat a blocked blood vessel in the brain (such as endovascular therapy or surgery)
- People who are in a deeply unresponsive state and require strong or repeated stimulation to respond (confirm with trial site for exact scoring details)
- People whose brain scans show any type of bleeding in or around the brain
- People who are pregnant
- People who have a pre-existing neurological or psychiatric condition that could affect the results
- People who are already taking part in another treatment-based clinical trial
- People who have another serious or life-threatening medical condition that could interfere with completing the study, affect how results are measured, or for whom the study drug may be harmful
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Manish Lavhale, Ph.D., Pharmazz India
Phone: +91(120)256-9779
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The proportion of patients with adverse events (AEs) and serious adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.